US2013129779A1PendingUtilityA1

Cattle reproductive disease vaccines

48
Assignee: DOMINOWSKI PAUL JOSEPHPriority: Aug 26, 2002Filed: Dec 28, 2012Published: May 23, 2013
Est. expiryAug 26, 2022(expired)· nominal 20-yr term from priority
Inventors:Paul Joseph DominowskiMark D. GoodyearMichael J. Huether
A61P 37/02A61P 31/12A61P 31/14A61P 31/04A61P 31/22A61P 37/04A61P 31/20A61P 39/00A61P 31/00A61P 11/00A61P 15/06A61P 15/00C12N 2770/28022C07K 14/005A61K 2039/5254C12N 2760/18522C12N 2720/10022C12N 2760/18622C12N 2770/24322A61K 2039/5252A61K 39/0225C12N 2710/16722A61K 39/39A61K 39/295A61K 39/00A61K 39/12A61K 39/155A61K 39/265
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI 3 ), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj - prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo - bovis and Leptospira pomona by administering to the animal an effective amount of a combination vaccine. The combination vaccine can be a whole or partial cell inactivated or modified live preparation.

Claims

exact text as granted — not AI-modified
1 .- 11 . (canceled) 
     
     
         12 . A method of inducing an immune response against Bovine Herpes Virus Type 1 in an animal subject, comprising administering an immunologically effective amount of the composition of claim  1  and a veterinary-acceptable carrier. 
     
     
         13 . A method of inducing an immune response against Bovine Viral Diarrhea Virus Type-1 in an animal subject, comprising administering an immunologically effective amount of the composition of claim  1  and a veterinary-acceptable carrier. 
     
     
         14 . A method of inducing an immune response against Bovine Viral Diarrhea Virus Type-2 in an animal subject, comprising administering an immunologically effective amount of the composition of claim  1  and a veterinary-acceptable carrier. 
     
     
         15 . A method of inducing an immune response against parainfluenza virus Type 3 (PI3) in an animal subject, comprising administering an immunologically effective amount of the composition of claim  1  and a veterinary-acceptable carrier. 
     
     
         16 . A method of inducing an immune response against Bovine Respiratory Syncytial Virus (BRSV) in an animal subject, comprising administering an immunologically effective amount of the composition of claim  1  and a veterinary-acceptable carrier. 
     
     
         17 . A method of inducing an immune response against  Campylobacter fetus  in an animal subject, comprising administering an immunologically effective amount of the composition of claim  1  and a veterinary-acceptable carrier. 
     
     
         18 . A method of inducing an immune response against an antigen selected from the group consisting of  Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardioprajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo - bovis, Leptospira bratislava, Neospora caninum, Trichomonus fetus, Mycoplasma, bovis, Haemophilus somnus, Mannheimia haemolytica  and  Pasturella multocida  in an animal subject, comprising administering an immunologically effective amount of the composition of claim  1  and a veterinary-acceptable carrier. 
     
     
         19 . The method of any one of  claims 12 - 18 , wherein said immune response is a cellular or humoral immune response. 
     
     
         20 .- 31 . (canceled) 
     
     
         32 . A method of preventing abortion caused by Bovine Herpes Virus (BHV-1) in an animal comprising administering to said animal a therapeutically effective amount of a vaccine composition comprising:
 a modified live Bovine Herpes Virus (BHV-1);   a modified live parainfluenza virus Type 3 (PI3);   a modified live Bovine Respiratory Syncytial Virus (BRSV);   a Bovine Viral Diarrhea Virus Type-1 (BVDV-1);   a Bovine Viral Diarrhea Virus Type-2 (BVDV-2);   an adjuvant; and   a veterinary-acceptable carrier.   
     
     
         33 . The method of  claim 32 , wherein said animal is a cow, a calf, a heifer, a steer or a bull. 
     
     
         34 . The method of  claim 33 , wherein said animal is a lactating cow. 
     
     
         35 . The method of  claim 33 , wherein said animal is a pregnant cow. 
     
     
         36 . The method of  claim 33 , wherein said animal is a prebreeding cow or heifer. 
     
     
         37 .- 38 . (canceled) 
     
     
         39 . The method of  claim 32 , wherein said vaccine contains from about 10 3  to about 10 10  colony forming units per dose of each virus. 
     
     
         40 . The method of  claim 32 , wherein the amount of said vaccine administered is from about 0.5 to about 5.0 ml per dose. 
     
     
         41 .- 42 . (canceled) 
     
     
         43 . A method of treating or preventing a disease or disorder in an animal caused by infection with a virus selected from the group consisting of BVDV Type 1 or Type 2, BHV-1, PI3 or BRSV comprising administering to said animal a therapeutically effective amount of the vaccine composition of claim  20 . 
     
     
         44 . The method of  claim 43 , wherein said animal is a cow, a calf, a heifer, a steer or a bull. 
     
     
         45 . The method of  claim 44 , wherein said animal is a lactating cow. 
     
     
         46 . The method of  claim 44 , wherein said animal is a prebreeding cow or heifer. 
     
     
         47 . The method of  claim 44 , wherein said animal is a pregnant cow. 
     
     
         48 . The method of  claim 43 , wherein said vaccine is administered intramuscularly. 
     
     
         49 . The method of  claim 43 , wherein said vaccine is administered subcutaneously. 
     
     
         50 . The method of  claim 43 , wherein said vaccine contains from about 10 3  to about 10 10  colony forming units per dose. 
     
     
         51 . The method of  claim 43 , wherein the amount of said vaccine administered is from about 0.5 to about 5.0 ml per dose. 
     
     
         52 . The method of  claim 51 , wherein the amount of said vaccine administered is about 5 ml per dose. 
     
     
         53 . The method of  claim 51 , wherein the amount of said vaccine administered is about 2 ml per dose. 
     
     
         54 . A method of treating or preventing a disease or disorder in an animal caused by infection with an antigen selected from the group consisting  Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardio - prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo - bovis, Leptospira Bratislava, Campylobacter fetus, Neospora caninum, Trichomonus fetus, Mycoplasma, bovis, Haemophilus somnus, Mannheimia haemolytica  and  Pasturella multocida , comprising administering to said animal a therapeutically effective amount of the vaccine composition of claim  20 . 
     
     
         55 . The method of  claim 54 , wherein said animal is a cow, a calf, a heifer, a steer or a bull. 
     
     
         56 . The method of  claim 55 , wherein said animal is a lactating cow. 
     
     
         57 . The method of  claim 55 , wherein said animal is a pregnant cow. 
     
     
         58 . The method of  claim 55 , wherein said animal is a prebreeding cow or heifer. 
     
     
         59 . The method of  claim 54 , wherein said vaccine is administered intramuscularly. 
     
     
         60 . The method of  claim 54 , wherein said vaccine is administered subcutaneously. 
     
     
         61 . The method of  claim 54 , wherein said vaccine contains from about 10 3  to about 10 10  colony forming units per dose of each virus. 
     
     
         62 . The method of  claim 54 , wherein the amount of said vaccine administered is from about 0.5 to about 5.0 ml per dose. 
     
     
         63 . The method of  claim 62 , wherein the amount of said vaccine administered is about 5 ml per dose. 
     
     
         64 . The method of  claim 62 , wherein the amount of said vaccine administered is about 2 ml per dose. 
     
     
         65 . A method of treating or preventing persistent fetal infection in an animal subject, comprising administering to said animal an effective amount of a vaccine composition comprising:
 a modified live Bovine Herpes Virus (BHV-1);   a modified live parainfluenza virus Type 3 (PI3);   a modified live Bovine Respiratory Syncytial Virus (BRSV);   a Bovine Viral Diarrhea Virus Type-1 (BVDV-1);   a Bovine Viral Diarrhea Virus Type-2 (BVDV-2);   an adjuvant; and   a veterinary-acceptable carrier.   
     
     
         66 . The method of  claim 65 , wherein said animal is a cow, a calf, a heifer, a steer or a bull. 
     
     
         67 . The method of  claim 66 , wherein said animal is a lactating cow. 
     
     
         68 . The method of  claim 66 , wherein said animal is a pregnant cow. 
     
     
         69 . The method of  claim 66 , wherein said animal is a prebreeding cow or heifer. 
     
     
         70 .- 71 . (canceled) 
     
     
         72 . The method of  claim 66 , wherein said vaccine contains from about 10 3  to about 10 10  colony forming units per dose of each virus. 
     
     
         73 . The method of  claim 65 , wherein the amount of said vaccine administered is from about 0.5 to about 5.0 ml per dose. 
     
     
         74 .- 83 . (canceled) 
     
     
         84 . The method of  claim 32 , wherein the composition further comprises at least one antigen selected from the group consisting of  Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo - prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo - bovis , and  Campylobacter fetus.    
     
     
         85 . The method of  claim 32 , wherein said adjuvant comprises a saponin-containing oil-in-water emulsion. 
     
     
         86 . The method of  claim 85 , wherein said saponin-containing oil-in-water emulsion is microfluidized. 
     
     
         87 . The method of  claim 32 , wherein said adjuvant comprises Quil A, cholesterol, and a lecithin and oil blend. 
     
     
         88 . The method of  claim 65 , wherein the composition further comprises at least one antigen selected from the group consisting of  Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo - prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo - bovis , and  Campylobacter fetus.    
     
     
         89 . The method of  claim 65 , wherein said adjuvant comprises a saponin-containing oil-in-water emulsion. 
     
     
         90 . The method of  claim 89 , wherein said saponin-containing oil-in-water emulsion is microfluidized. 
     
     
         91 . The method of  claim 65 , wherein said adjuvant comprises Quil A, cholesterol, and a lecithin and oil blend.

Join the waitlist — get patent alerts

Track US2013129779A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.